난소암

203개 · ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved203 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

ADCLimited DatastaleThe First Affiliated Hospital o…Phase 2

sacituzumab govitecan (Trodelvy, Sacituzumab Tirumotecan Combined with Bevacizumab)

Platinum-resistant Recurrent Ovarian Cancer (PROC) · Platinum-resistant Recurrent Ovarian Can

#Platinum-resistantRecurrentOvari#ADC#Phase2#antibody-drug-conjugate#The
Trials 1Status Recruiting
CGTLimited DatastalePersonGen BioTherapeutics (Suzh…Phase 1

T cell injection targeting B7-H3 chimeric antigen receptor (T cell injection targeting B7-H3 chimeric antigen receptor)

B7-H3-positive Relapsed/ Refractory Neuroblastoma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastalePersonGen BioTherapeutics (Suzh…Phase 1

T cell injection targeting FLT3 chimeric antigen receptor (T cell injection targeting FLT3 chimeric antigen receptor)

FLT3-positive Relapsed/Refractory Acute Myeloid Leukemia · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Active
AntibodyLimited DatastaleHoffmann-La RochePhase 3

Tociluzumab (Tociluzumab)

Relapsed or Refractory Follicular Lymphoma · FRα

#FR#Antibody#Phase3#monoclonal-antibody#RelapsedorRefractoryFollicularLy+1
Trials 1Status Recruiting
ADCLimited DatastaleBoryung Pharmaceutical Co., LtdPhase 2

Trastzumab Deruxtecan (Trastzumab Deruxtecan)

Ovarian Cancer; Ovarian Carcinoma, Recurrent · Ovarian Cancer

#OvarianCancer#ADC#Phase2#antibody-drug-conjugate#OvarianCarcinoma+2
Trials 1Status Recruiting
AntibodyLimited DatastaleRochePhase 2

Trifluridine-tipiracil plus Bevacizumab Alone (Trifluridine-tipiracil plus Bevacizumab Alone)

Refractory Metastatic Colorectal Cancer · FRα

#FR#Antibody#Phase2#monoclonal-antibody#RefractoryMetastaticColorectalCa+1
Trials 1Status Recruiting
CGTLimited DatastaleCellectis S.A.Phase 1

UCART123v1.2 (UCART123v1.2)

Relapsed/Refractory Acute Myeloid Leukemia · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleCellectis S.A.Phase 1

UCARTCS1A (UCARTCS1A)

Relapsed/Refractory Multiple Myeloma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Discontinued
AntibodyLimited DatastaleMersana TherapeuticsPhase 3

Upifitimab rilsodotin (Upifitimab rilsodotin)

High Grade Serous Ovarian Cancer; Fallopian Tube Cancer · High Grade Serous Ovarian Cancer

#HighGradeSerousOvarianCancer#Antibody#Phase3#monoclonal-antibody#FallopianTubeCancer+1
Trials 1Status Discontinued
AntibodyLimited DatastaleXencor, Inc.Phase 1

XmAb808 (XmAb808)

Ovarian Cancer · Ovarian Cancer

#OvarianCancer#Antibody#Phase1#monoclonal-antibody#Xencor
Trials 1Status Recruiting
CGTAAVLimited DatastaleYAP Therapeutics, Inc.Phase 1

AAV9-Sav-shRNA (YAP101, YAP101 (AAV9-Sav-shRNA))

Heart Failure With Reduced Ejection Fraction · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
AntibodyLimited DatastaleNational Cancer Institute (NCI)Phase 1

aflibercept (Eylea, VEGF Trap-Eye, Eylea HD, Ziv-Aflibercept)

Clinical Stage IV Cutaneous Melanoma AJCC v8; Metastatic Colorectal Carcinoma · FRα

#FR#Antibody#Phase1#monoclonal-antibody#ClinicalStageIVCutaneousMelanoma+2
Trials 1Status Recruiting
CGTLimited DatastaleNanjing Legend Biotech Co.Phase 1

anti-CD123 CAR-T treatment (anti-CD123 CAR-T treatment)

Acute Leukemia; Acute Leukemia in Relapse · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Discontinued
AntibodyLimited DatastaleNational Cancer Institute (NCI)Phase 2

apolizumab (apolizumab)

Noncontiguous Stage II Small Lymphocytic Lymphoma; Recurrent Small Lymphocytic Lymphoma · FRα

#FR#Antibody#Phase2#monoclonal-antibody#NoncontiguousStageIISmallLymphoc+2
Trials 1Status Active
CGTLimited DatastaleBeijing GoBroad HospitalPhase 1

autologous FL-33 CAR T therapy (autologous FL-33 CAR T therapy)

Refractory/Relapsed Acute Myeloid Leukaemia · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleYuLiPhase 2

dual target CAR-T cell therapy (dual target CAR-T cell therapy)

Lymphoma, B-Cell; Relapse/Recurrence · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 1Status Active
CGTLimited DatastaleFollicular Lymphoma FoundationPhase 1

huCART19-IL18-eDHFR cells (huCART19-IL18-eDHFR cells)

Relapsed or Refractory Follicular Lymphoma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleBaylor College of MedicinePhase 1

i15.NKG2D.zeta NK cells and C7R.GD2.CARTs cells (i15.NKG2D.zeta NK cells and C7R.GD2.CARTs cells)

Relapsed Neuroblastoma; Refractory Neuroblastoma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleUNC Lineberger Comprehensive Ca…Phase 1

iC9-CAR.B7-H3 T cells (iC9-CAR.B7-H3 T cells)

Ovary Neoplasm; Ovarian Cancer · B7-H3

#B7-H3#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
AntibodyLimited DatastaleShahid Beheshti University of M…Phase 3

injection of bevacizumab (injection of bevacizumab)

Refractory Diabetic Macular Edema · FRα

#FR#Antibody#Phase3#monoclonal-antibody#RefractoryDiabeticMacularEdema+1
Trials 1Status Active

10 / 11 pages

← PreviousNext →